New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2012
06:55 EDTSHPGY, SHPGY, SHPGY, INFI, INFI, INFI, AMGN, AMGN, AMGN, LXRX, LXRX, LXRX, ZGNX, ZGNX, ZGNX, EPCT, EPCT, EPCT, MRK, MRK, MRK, BIIB, BIIB, BIIB, AZN, AZN, AZN, GSK, GSK, GSK, CELG, CELG, CELG, KFY, KFY, KFYElsevier Business Intelligence to host a conference
Pharmaceutical Strategic Outlook: Biopharma Strategic Dealmaking Conference is being held in New York on April 11-13 with pre-conference workshops being held on April 11 and the conference starting on April 12 at 8 am.
News For KFY;CELG;GSK;AZN;BIIB;MRK;EPCT;ZGNX;LXRX;AMGN;INFI;SHPGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 18, 2015
07:34 EDTBIIBBiogen should report strong Alzheimer's data, says RBC Capital
Subscribe for More Information
March 17, 2015
16:11 EDTAMGNAmgen to present 10 abstracts from dermatology portfolio
Subscribe for More Information
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
07:07 EDTGSKVeeva says selected by GlaxoSmithKline for multichannel CRM
Subscribe for More Information
07:06 EDTGSKVeeva selected by GSK as global multichannel CRM partner
Subscribe for More Information
March 16, 2015
15:33 EDTMRKMerck says study shows VYTORIN reduced CV events more than simvastatin alone
Subscribe for More Information
08:52 EDTAMGNAmgen to hold a conference call
Conference call to provide an update from the 73rd Annual Meeting of AAD will be held on March 23 at 3 pm. Webcast Link
08:35 EDTAMGNAmgen to hold a conference call
Executive Vice President of R&D, Sean Harper, discusses Amgen's cardiovascular program, including the Repatha data currently being presented at the American College of Cardiology's Scientific Session & Expo, on a conference call to be held on March 16 at 4 pm. Webcast Link
08:23 EDTAMGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:32 EDTGSKEmergent BioSolutions signs agreements with GSK, Oxford University, NIAID
Subscribe for More Information
07:30 EDTAZNAmerican College of Cardiology to hold an expo
Subscribe for More Information
06:57 EDTAMGNAmgen clinical data very positive, says RBC Capital
Subscribe for More Information
06:40 EDTAMGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:11 EDTAMGNAmgen publishes safety analysis of Repatha in New England Journal of Medicine
Subscribe for More Information
12:53 EDTAMGNAmgen announces new data from study of Repatha in combination with statins
Subscribe for More Information
March 13, 2015
17:33 EDTCELGS&P announces changes to S&P 100 Index
Subscribe for More Information
16:04 EDTMRKMerck provides update on investigational medicine sugammadex injection
Subscribe for More Information
11:19 EDTAZNBioMarin rallies amid positive call on DMD drug timeline, takeover rumor
The shares of drug maker BioMarin (BMRN) are climbing after research firm Jefferies quoted a regulatory expert as saying that the company's drisapersen drug has a good chance of being approved on an accelerated basis by the FDA. Drisapersen is a treatment for Duchenne Muscular Dystrophy, or DMD. WHAT'S NEW: "There is a strong possibility" that the FDA will grant accelerated approval to drisapersen because there is currently no approved drug for the treatment of DMD, Jefferies analyst Eun Yang quoted the expert as saying. The expert is also optimistic about the outlook for accelerated approval because she had a good experience working with BioMarin while she was with the FDA and because BioMarin has a favorable track record with the FDA, according to Yang. There is a 60% chance that drisapersen will be approved by the end of this year and the stock can rise to $155, versus its current level of about $121.50, if that does occur, the analyst stated. Yang's price target on the stock increased to $135 from $125 and the analyst kept a Buy rating on the shares. WHAT'S NOTABLE: Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash, British newspaper Daily Mail reported. , Piper Jaffray analyst Joshua Schimmer wrote in a note to investors this morning that BioMarin, along with Vertex (VRTX) and Incyte (INCY), have a "clear path" to joining the group of companies with market caps of over $10B projected to deliver greater than 20% EPS CAGR, which the analyst identified as a set of criteria that has previously pointed to companies that make good potential takeover targets. PRICE ACTION: In mid-morning trading, BioMarin climbed nearly 4% to $120.
08:35 EDTBIIBBiogen shares have additional room to run, says JPMorgan
JPMorgan says it would remain a buyer of Biogen ahead of the interim Phase 1b BIIB037 Alzheimer's update on March 20. It believes investors still incorporate a low probability of success for the asset. JPMorgan believes shares have additional upside potential despite the 20% rally year-to-date and keeps an Overweight rating on Biogen with a $420 price target.
08:07 EDTAZNAstraZeneca rumored to have BioMarin 'on shopping list,' Daily Mail says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use